Huapont Life Sciences (002004.SZ) has cumulatively spent 15.5856 million yuan to repurchase 0.18% of its shares.
On June 3rd, Grong Hui reported that Huapont Life Sciences (002004.SZ) announced that as of May 31, 2024, the company had repurchased a total of 3,505,808 shares through centralized trading, accounting for 0.18% of the company's current total share capital. The highest fill price was 4.65 yuan/share, and the lowest fill price was 3.88 yuan/share. The total amount paid was 15,585,611.15 yuan (excluding transaction fees). This repurchase is in line with the company's share repurchase plan and relevant laws and regulations.
Do These 3 Checks Before Buying Huapont Life Sciences Co.,Ltd (SZSE:002004) For Its Upcoming Dividend
Huapont Life Sciences Co.,Ltd (SZSE:002004) is about to trade ex-dividend in the next 3 days. The ex-dividend date is usually set to be one business day before the record date which is the cut-off da
Huabang Health (002004.SZ) will pay 2.2 yuan for every 10 shares in 2023. The share registration date is May 31
Huabang Health (002004.SZ) announced that the company will implement the 2023 equity distribution to all shareholders...
Huabang Health (002004.SZ): No related products are involved in synthetic biology
Gelonghui, May 10 | Huabang Health (002004.SZ) said on the investor interactive platform that in terms of synthetic biology, the company has not yet involved related products, but the company will actively experiment with synthetic biology technology and keep a close eye on related policy developments. In terms of stem cells, the company's shareholders are involved in related businesses: 1. Hebei Life Origin Biotechnology Co., Ltd. is the builder and operator of the Hebei Stem Cell Bank. Its core business is cell storage business such as neonatal stem cells, adult immune cells, etc., and clinical research and application transformation of stem cell products. 2. Jiangsu Puxin Biomedical Co., Ltd. is mainly engaged in cell and gene therapy
Huapont Life SciencesLtd's (SZSE:002004) Conservative Accounting Might Explain Soft Earnings
The market was pleased with the recent earnings report from Huapont Life Sciences Co.,Ltd (SZSE:002004), despite the profit numbers being soft. However, we think the company is showing some signs tha
Huapont Life SciencesLtd (SZSE:002004) Has A Somewhat Strained Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Huabang Health (002004.SZ) announced first-quarter results, net profit of 156 million yuan, a decrease of 12.18%
Huabang Health (002004.SZ) released its report for the first quarter of 2024, achieving operating income of 29 during the reporting period...
Returns At Huapont Life SciencesLtd (SZSE:002004) Appear To Be Weighed Down
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and al
Huabang Health (002004.SZ): The holding subsidiary Kaisheng New Materials is mainly engaged in R&D, production and sales of fine chemical products and new polymer materials
Gelonghui, March 13 | Huabang Health (002004.SZ) said on the investor interactive platform that the company's holding subsidiary Kaisheng New Materials is mainly engaged in R&D, production and sales of fine chemical products and novel polymer materials. The business covers inorganic chemicals, carboxyl chlorides, hydroxychlorides, and the novel polymer material polyether ketone. The main products include inorganic chemicals (including sulfoxide chloride and sulfuryl chloride), carboxyl chloride (including aramid polymer monomers, para-nitrobenzoyl chloride, chloroacetyl chloride, etc.), hydroxychlorides (including chloroacetyl chloride, etc.), hydroxychlorides (including chloroacetyl chloride, etc.), hydroxy chlorides (including chloroacetyl chloride, etc.), and polychlorochlorides (including polychlorinated polymers) ether ketone ketone, etc.
Huabang Health (002004.SZ): Controlling shareholders pledge 4.3 million shares
Gelonghui, Feb. 7 | Huabang Health (002004.SZ) announced that the company recently received a notice from Xizang Huibang Technology Co., Ltd. (“Huibang Technology”), the holding stock of the company, and learned that it will pledge some of the company's shares. The number of shares pledged this time is 4.3 million shares.
Huabang Health (002004.SZ): A total cost of 15.27 million yuan to buy back 3.355,800 shares
Gelonghui, Feb. 1 | Huabang Health (002004.SZ) announced that as of January 31, 2024, the company had repurchased a total of 33558.08 million shares through centralized trading, accounting for 0.17% of the company's current total share capital. The highest transaction price was 4.65 yuan/share, the lowest transaction price was 4.23 yuan/share, and the total amount paid was 15.027 million yuan (not including transaction fees).
Here's Why Huapont Life SciencesLtd (SZSE:002004) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Huabang Health (002004.SZ): As of the end of the third quarter of 2023, the company's travel sector revenue exceeded 900 million yuan
Gelonghui, January 17 | Huabang Health (002004.SZ) said on the investor interactive platform that the company's tourism resources are widely distributed in various 5A scenic spots in Yunnan, Shaanxi, Chongqing, Guangxi, etc., and its business covers scenic ropeway transportation, hotel management, tourism and entertainment. By the end of the third quarter of 2023, the company's travel sector had revenue of over 900 million yuan.
Huabang Health (002004.SZ): Initial repurchase of 870,000 shares involving 4,023,800 yuan
Gelonghui, January 8, 丨 Huabang Health (002004.SZ) announced that on January 8, 2024, the company implemented the first repurchase. According to relevant regulations, the implementation status is now announced as follows: the number of shares repurchased by the company for the first time through centralized bidding transactions is 870,000 shares, accounting for 0.04% of the company's total share capital, minimum transaction price 4.61 yuan/share, maximum transaction price 4.64 yuan/share, and the total repurchase amount paid is 4,023,800 yuan (excluding transaction fees such as commissions and transfer fees).
Huabang Health (002004.SZ): Prescription drugs such as adapalene gel and tretinoin cream produced have a certain effect on treating acne pits
Gelonghui, January 4 | Huabang Health (002004.SZ) said on the investor interactive platform that prescription drugs such as adapalene gel and tretinoin cream produced by the company have certain effects on acne pits treatment. It is recommended that you seek advice and guidance from a professional doctor. It is recommended that you seek advice and guidance from a doctor based on factors such as the type, severity and skin condition of the acne pits, and use the medication according to doctor's instructions. In addition, in terms of functional skincare products, the azelaic acid series products launched by the company's Sanrui brand have a certain auxiliary effect on the recovery of acne pits. Related products can be searched on Taobao's “Huabang Pharmaceutical Sanrui Skincare Store”, Tmall's “Sanrui Cosmetics Flagship Store”, and Beijing
Huabang Health (002004.SZ): Plans to spend 20 million yuan to 30 million yuan to buy back the company's shares
On December 27, Gelonghui | Huabang Health (002004.SZ) announced an announcement on the plan to repurchase the company's shares. The total capital of this repurchase is not less than RMB 20 million (inclusive) and not more than RMB 30 million (inclusive). The repurchase price is not higher than RMB 7.21 per share. Equity incentive plans or employee stock ownership plans for repurchase purposes. According to the maximum repurchase amount and maximum repurchase price, the estimated number of shares that can be repurchased is about 4,160,888 shares, accounting for 0.21% of the current total share capital of the company; based on the lower repurchase amount and upper repurchase price, the estimated number of shares that can be repurchased is approximately
Huabang Health (002004.SZ): A novel nanoantibody drug for psoriasis is being developed and is currently in the pre-clinical research stage
Glonghui, December 4, Huabang Health (002004.SZ) said on an interactive platform that for a long time, the company has set up 3-5 products on a rolling basis every year to ensure product iteration and new product research and development, thus achieving full coverage of dermatologic drugs. In terms of innovative drugs, the company and participating company Pregin are collaborating to develop a novel nanoantibody drug to treat psoriasis, which is currently in the pre-clinical research stage.
Huabang Health (002004.SZ): Has supplied high-purity battery-grade sulfoxide chloride to some electrolyte manufacturers
Glonghui November 20 | Huabang Health (002004.SZ) recently stated at an online investor reception day event that compared to ordinary industrial grade, battery-grade sulfoxide chloride has higher purity and fewer impurities and content. Since lithium bifluorosulfonimide (LiFSi) products have not yet been scaled up on a large scale, battery grade sulfoxide currently accounts for a small proportion of total sulfoxide chloride shipments. In the future, with the gradual release of LiFSI products, demand for battery-grade sulfoxide chloride will gradually increase. Currently, the company has a production capacity of 150,000 tons/year of sulfoxide chloride, and has supplied high-purity battery-grade chlorine to some electrolyte manufacturers
Huabang Health (002004.SZ): Kaisheng New Materials currently has a production capacity of 31,000 tons/year for aramid monomers
Glonghui November 20 | Huabang Health (002004.SZ) recently stated at an online investor reception day event that the lower sales price of sulfoxide chloride products this year is mainly related to raw material procurement prices and sluggish demand in the downstream pesticide market, and is cyclical to a certain extent. Kaisheng New Materials, a holding subsidiary of the company, will firmly implement the one-chain, two-wing development strategy. Based on the sulfoxide chloride industry chain, it will continue to develop new applications and products downstream, thereby increasing the added value of sulfoxide chloride derivatives. Kaisheng New Materials currently has a production capacity of 31,000 tons/year for aramid monomers, and is also raising capital to build new production capacity to meet customer expectations
Huabang Health (002004.SZ): Its tourism companies, led by Lijiang Co., Ltd., have clearly recovered
Glonghui November 20 | Huabang Health (002004.SZ) recently stated at an online investor reception day event that since this year, the domestic travel market has been picking up overall, and the company's tourism enterprises, led by Lijiang Co., Ltd., have clearly recovered, and the number of visitors has increased significantly compared to the same period last year. In the future, the company will strive to improve the quality of tourist services, focus on marketing and promotion efforts, actively improve the company's business vitality, and bring visitors a more comfortable, convenient and satisfying experience.
No Data